Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer.

por van der Gaast, A., van Putten, W. L., Oosterom, R., Cozijnsen, M., Hoekstra, R., Splinter, T. A.
Publicado 1991

Response to adjuvant chemotherapy in primary breast cancer: no correlation with expression of glutathione S-transferases.

por Peters, W. H., Roelofs, H. M., van Putten, W. L., Jansen, J. B., Klijn, J. G., Foekens, J. A.
Publicado 1993

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.

por Foekens, J. A., Portengen, H., Look, M. P., van Putten, W. L., Thirion, B., Bontenbal, M., Klijn, J. G.
Publicado 1994

Prognostic value of cytosolic tyrosine kinase activity in 249 node-positive breast cancer patients.

por Romain, S., Chinot, O., Klijn, J. G., van Putten, W. L., Guirou, O., Look, M., Martin, P. M., Foekens, J. A.
Publicado 1994

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.

por Hilkens, P. H., Pronk, L. C., Verweij, J., Vecht, C. J., van Putten, W. L., van den Bent, M. J.
Publicado 1997

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

por van der Burg, M E L, de Wit, R, van Putten, W L J, Logmans, A, Kruit, W H J, Stoter, G, Verweij, J
Publicado 2002

Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cance...

por Bontenbal, M., Foekens, J. A., Lamberts, S. W., de Jong, F. H., van Putten, W. L., Braun, H. J., Burghouts, J. T., van der Linden, G. H., Klijn, J. G.
Publicado 1998

Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients

por de Witte, J H, Sweep, C G J, Klijn, J G M, Grebenschikov, N, Peters, H A, Look, M P, van Tienoven, Th H, Heuvel, J J T M, van Putten, W L J, Benraad, Th J, Foekens, J A
Publicado 1999

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy

por Wortman, B. G., Creutzberg, C. L., Putter, H., Jürgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen-Banasik, E. M., Mens, J. W. M., Slot, A., Kroese, M. C. Stenfert, van Triest, B., Nijman, H. W., Stelloo, E., Bosse, T., de Boer, S. M., van Putten, W. L. J., Smit, V. T. H. B. M, Nout, R. A.
Publicado 2018